カテゴリ： LP Information, 世界, 医療/バイオ

微小管阻害薬の世界市場2022-2028：重合阻害剤、解重合阻害剤、微小管ダイナミクス阻害剤、抗体薬物複合体（ADC）

■ 英語タイトル：Global Microtubule Inhibitor Drugs Market Growth 2022-2028
	■ 発行会社/調査会社：LP Information ■ 商品コード：LP22DC5024 ■ 発行日：2022年12月 ■ 調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など ■ 産業分野：医薬品 ■ ページ数：100 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（受注後2-3営業日）

■ 販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,660 ⇒換算￥556,320	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD5,490 ⇒換算￥834,480	見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）	USD7,320 ⇒換算￥1,112,640	見積依頼/購入/質問フォーム

※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※LP Information社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[微小管阻害薬の世界市場2022-2028：重合阻害剤、解重合阻害剤、微小管ダイナミクス阻害剤、抗体薬物複合体（ADC）]についてメールでお問い合わせはこちら

*** レポート概要（サマリー）***

微小管阻害薬のグローバル市場規模は、2021年のxxx百万ドルから2028年までにxxx百万ドルに増加すると推定されており、2022年～2028年の年平均成長率（CAGR）はxx%を示しています。COVID-19とロシア・ウクライナ戦争の不確実性を念頭に置いて、さまざまな最終用途部門に対するパンデミックの直接的および間接的な影響を継続的に追跡・分析しています。これらのインサイトは、主要な市場要因としてレポートに含まれています。
微小管阻害薬のアジア太平洋市場は、2022年にxxx百万ドルの市場規模が見込まれ、2022年～2028年にかけて約xx%のCAGRで成長すると予想されています。微小管阻害薬の米国市場は、2022年にxxx百万ドルの規模があり、2022年～2028年にかけて約xx%のCAGRで成長すると予想されています。微小管阻害薬のヨーロッパ市場は、2022年にxxx百万ドルの規模が見込まれ、2022年～2028年にかけて約xx%のCAGRで成長すると予想されています。微小管阻害薬の中国市場は、2022年にxxx百万ドルの規模があり、2022年～2028年にかけて約xx%のCAGRで成長すると予想されています。

世界の主要な微小管阻害薬関連企業としては、Eli Lilly and Company、 Bristol-Myers Squibb、 Sanofi、 Pierre Fabre、 Eisai、 Celgene、 Merck、 Roche Holding AG、 Seagen、 Luye Pharma、 Shanghai Yizhong、 Biostar Pharmaceuticalsなどをカバーしています。売上の面では世界最大の2社が2021年にほぼxx%の市場シェアを占めています。

*** レポート範囲 ***

この最新のレポートはすべての重要な側面をカバーしながら微小管阻害薬のグローバル市場に関する深いインサイトを提供します。これは、市場のマクロな概要から、市場規模、競争環境、開発動向、ニッチ市場、主要な市場ドライバーと課題、バリューチェーン分析などのミクロの詳細にまで及びます。当レポートは読者がパンデミックおよびロシア・ウクライナ戦争中に世界中で微小管阻害薬市場シナリオがどのように変化したかを理解できるように定量的データと定性的データの両方を使用して、微小管阻害薬のグローバル市場の全体像を提供することを目的としています。

分析の対象となる基準年は2021年で、市場の予測は2022年～2028年までのものです。

*** 市場セグメンテーション ***

この調査では微小管阻害薬市場を細分化し、種類別 (重合阻害剤、解重合阻害剤、微小管ダイナミクス阻害剤、抗体薬物複合体（ADC）)、用途別 (乳がん、胃がん、肺がん、食道がん、その他)、および地域別 (アジア太平洋、アメリカ州、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：重合阻害剤、解重合阻害剤、微小管ダイナミクス阻害剤、抗体薬物複合体（ADC）

・用途別区分：乳がん、胃がん、肺がん、食道がん、その他

・地域別区分
アメリカ州（アメリカ、カナダ、メキシコ、ブラジル）
APAC/アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

*** 各章の紹介 ***
第1章：微小管阻害薬の範囲、調査方法など
第2章：エグゼクティブサマリー、世界の微小管阻害薬市場規模 (販売量、売上) およびCAGR、地域別・種類別・用途別、2017年～2022年までの推移データ、および2028年までの市場予測
第3章：企業別微小管阻害薬の販売量、売上、平均価格、グローバル市場シェア、および業界ランキング
第4章：地域別および国別の微小管阻害薬の販売量と売上（米国、カナダ、ヨーロッパ、中国、日本、韓国、東南アジア、インド、ラテンアメリカ、中東・アフリカなど）
第5/6/7/8章：アメリカ州、アジア太平洋、ヨーロッパ、中東・アフリカの国別、種類別の販売セグメント
第9章：市場動向、市場予測、機会、将来の市場に影響を与える経済動向の分析
第10章：製造コスト構造分析
第11章：販売チャンネル、販売業者および顧客
第12章：地域別、国別、種類別、用途別の世界の微小管阻害薬市場規模予測
第13章：主要企業の包括的な企業プロファイル
第14章：調査の結果

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：微小管阻害薬の年間販売量2017-2028、地域別現状・将来分析
・微小管阻害薬の種類別セグメント：重合阻害剤、解重合阻害剤、微小管ダイナミクス阻害剤、抗体薬物複合体（ADC）
・微小管阻害薬の種類別販売量：2017-2022年の販売量、売上、市場シェア、販売価格
・微小管阻害薬の用途別セグメント：乳がん、胃がん、肺がん、食道がん、その他
・微小管阻害薬の用途別販売量：2017-2022年の販売量、売上、市場シェア、販売価格

企業別世界の微小管阻害薬市場
・企業別のグローバル微小管阻害薬市場データ：2020-2022年の年間販売量、市場シェア
・企業別の微小管阻害薬の年間売上：2020-2022年の売上、市場シェア
・企業別の微小管阻害薬販売価格
・主要企業の微小管阻害薬生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

微小管阻害薬の地域別レビュー
・地域別の微小管阻害薬市場規模2017-2022：年間販売量、売上
・主要国別の微小管阻害薬市場規模2017-2022：年間販売量、売上
・アメリカ州の微小管阻害薬販売の成長
・アジア太平洋の微小管阻害薬販売の成長
・ヨーロッパの微小管阻害薬販売の成長
・中東・アフリカの微小管阻害薬販売の成長

アメリカ州市場
・アメリカ州の国別の微小管阻害薬販売量、売上（2017-2022）
・アメリカ州の微小管阻害薬の種類別販売量
・アメリカ州の微小管阻害薬の用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋（APAC）市場
・アジア太平洋の国別の微小管阻害薬販売量、売上（2017-2022）
・アジア太平洋の微小管阻害薬の種類別販売量
・アジア太平洋の微小管阻害薬の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の微小管阻害薬販売量、売上（2017-2022）
・ヨーロッパの微小管阻害薬の種類別販売量
・ヨーロッパの微小管阻害薬の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の微小管阻害薬販売量、売上（2017-2022）
・中東・アフリカの微小管阻害薬の種類別販売量
・中東・アフリカの微小管阻害薬の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・微小管阻害薬の製造コスト構造分析
・微小管阻害薬の製造プロセス分析
・微小管阻害薬の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・微小管阻害薬の主要なグローバル販売業者
・微小管阻害薬の主要なグローバル顧客

地域別の微小管阻害薬市場予測レビュー
・地域別の微小管阻害薬市場規模予測（2023-2028）
・アメリカ州の国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・微小管阻害薬の種類別市場規模予測
・微小管阻害薬の用途別市場規模予測

主要企業分析
Eli Lilly and Company、 Bristol-Myers Squibb、 Sanofi、 Pierre Fabre、 Eisai、 Celgene、 Merck、 Roche Holding AG、 Seagen、 Luye Pharma、 Shanghai Yizhong、 Biostar Pharmaceuticals
・企業情報
・微小管阻害薬製品
・微小管阻害薬販売量、売上、価格、粗利益（2020-2022）
・主要ビジネス概要
・最新動向

調査の結果

The global market for Microtubule Inhibitor Drugs is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Microtubule Inhibitor Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Microtubule Inhibitor Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Microtubule Inhibitor Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Microtubule Inhibitor Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Microtubule Inhibitor Drugs players cover Eli Lilly and Company, Bristol-Myers Squibb, Sanofi, Pierre Fabre and Eisai, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

[Report Coverage]
This latest report provides a deep insight into the global Microtubule Inhibitor Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Microtubule Inhibitor Drugs market, with both quantitative and qualitative data, to help readers understand how the Microtubule Inhibitor Drugs market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

[Market Segmentation]
The study segments the Microtubule Inhibitor Drugs market and forecasts the market size by Type (Polymerization Inhibitor, Depolymerization Inhibitor and Microtubule Dynamics Inhibitor), by Application (Breast Cancer, Stomach Cancer, Lung Cancer and Esophageal Cancer), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Polymerization Inhibitor
Depolymerization Inhibitor
Microtubule Dynamics Inhibitor
Antibody Drug Conjugates(ADC)
Segmentation by application
Breast Cancer
Stomach Cancer
Lung Cancer
Esophageal Cancer
Others
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Eli Lilly and Company
Bristol-Myers Squibb
Sanofi
Pierre Fabre
Eisai
Celgene
Merck
Roche Holding AG
Seagen
Luye Pharma
Shanghai Yizhong
Biostar Pharmaceuticals

[Chapter Introduction]
Chapter 1: Scope of Microtubule Inhibitor Drugs, Research Methodology, etc.
Chapter 2: Executive Summary, global Microtubule Inhibitor Drugs market size (sales and revenue) and CAGR, Microtubule Inhibitor Drugs market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Microtubule Inhibitor Drugs sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Microtubule Inhibitor Drugs sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Microtubule Inhibitor Drugs market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Eli Lilly and Company, Bristol-Myers Squibb, Sanofi, Pierre Fabre, Eisai, Celgene, Merck, Roche Holding AG and Seagen, etc.
Chapter 14: Research Findings and Conclusion

*** レポート目次（コンテンツ）***

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Microtubule Inhibitor Drugs Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Microtubule Inhibitor Drugs by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Microtubule Inhibitor Drugs by Country/Region, 2017, 2022 & 2028
2.2 Microtubule Inhibitor Drugs Segment by Type
2.2.1 Polymerization Inhibitor
2.2.2 Depolymerization Inhibitor
2.2.3 Microtubule Dynamics Inhibitor
2.2.4 Antibody Drug Conjugates(ADC)
2.3 Microtubule Inhibitor Drugs Sales by Type
2.3.1 Global Microtubule Inhibitor Drugs Sales Market Share by Type (2017-2022)
2.3.2 Global Microtubule Inhibitor Drugs Revenue and Market Share by Type (2017-2022)
2.3.3 Global Microtubule Inhibitor Drugs Sale Price by Type (2017-2022)
2.4 Microtubule Inhibitor Drugs Segment by Application
2.4.1 Breast Cancer
2.4.2 Stomach Cancer
2.4.3 Lung Cancer
2.4.4 Esophageal Cancer
2.4.5 Others
2.5 Microtubule Inhibitor Drugs Sales by Application
2.5.1 Global Microtubule Inhibitor Drugs Sale Market Share by Application (2017-2022)
2.5.2 Global Microtubule Inhibitor Drugs Revenue and Market Share by Application (2017-2022)
2.5.3 Global Microtubule Inhibitor Drugs Sale Price by Application (2017-2022)
3 Global Microtubule Inhibitor Drugs by Company
3.1 Global Microtubule Inhibitor Drugs Breakdown Data by Company
3.1.1 Global Microtubule Inhibitor Drugs Annual Sales by Company (2020-2022)
3.1.2 Global Microtubule Inhibitor Drugs Sales Market Share by Company (2020-2022)
3.2 Global Microtubule Inhibitor Drugs Annual Revenue by Company (2020-2022)
3.2.1 Global Microtubule Inhibitor Drugs Revenue by Company (2020-2022)
3.2.2 Global Microtubule Inhibitor Drugs Revenue Market Share by Company (2020-2022)
3.3 Global Microtubule Inhibitor Drugs Sale Price by Company
3.4 Key Manufacturers Microtubule Inhibitor Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Microtubule Inhibitor Drugs Product Location Distribution
3.4.2 Players Microtubule Inhibitor Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Microtubule Inhibitor Drugs by Geographic Region
4.1 World Historic Microtubule Inhibitor Drugs Market Size by Geographic Region (2017-2022)
4.1.1 Global Microtubule Inhibitor Drugs Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Microtubule Inhibitor Drugs Annual Revenue by Geographic Region
4.2 World Historic Microtubule Inhibitor Drugs Market Size by Country/Region (2017-2022)
4.2.1 Global Microtubule Inhibitor Drugs Annual Sales by Country/Region (2017-2022)
4.2.2 Global Microtubule Inhibitor Drugs Annual Revenue by Country/Region
4.3 Americas Microtubule Inhibitor Drugs Sales Growth
4.4 APAC Microtubule Inhibitor Drugs Sales Growth
4.5 Europe Microtubule Inhibitor Drugs Sales Growth
4.6 Middle East & Africa Microtubule Inhibitor Drugs Sales Growth
5 Americas
5.1 Americas Microtubule Inhibitor Drugs Sales by Country
5.1.1 Americas Microtubule Inhibitor Drugs Sales by Country (2017-2022)
5.1.2 Americas Microtubule Inhibitor Drugs Revenue by Country (2017-2022)
5.2 Americas Microtubule Inhibitor Drugs Sales by Type
5.3 Americas Microtubule Inhibitor Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Microtubule Inhibitor Drugs Sales by Region
6.1.1 APAC Microtubule Inhibitor Drugs Sales by Region (2017-2022)
6.1.2 APAC Microtubule Inhibitor Drugs Revenue by Region (2017-2022)
6.2 APAC Microtubule Inhibitor Drugs Sales by Type
6.3 APAC Microtubule Inhibitor Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Microtubule Inhibitor Drugs by Country
7.1.1 Europe Microtubule Inhibitor Drugs Sales by Country (2017-2022)
7.1.2 Europe Microtubule Inhibitor Drugs Revenue by Country (2017-2022)
7.2 Europe Microtubule Inhibitor Drugs Sales by Type
7.3 Europe Microtubule Inhibitor Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Microtubule Inhibitor Drugs by Country
8.1.1 Middle East & Africa Microtubule Inhibitor Drugs Sales by Country (2017-2022)
8.1.2 Middle East & Africa Microtubule Inhibitor Drugs Revenue by Country (2017-2022)
8.2 Middle East & Africa Microtubule Inhibitor Drugs Sales by Type
8.3 Middle East & Africa Microtubule Inhibitor Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Microtubule Inhibitor Drugs
10.3 Manufacturing Process Analysis of Microtubule Inhibitor Drugs
10.4 Industry Chain Structure of Microtubule Inhibitor Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Microtubule Inhibitor Drugs Distributors
11.3 Microtubule Inhibitor Drugs Customer
12 World Forecast Review for Microtubule Inhibitor Drugs by Geographic Region
12.1 Global Microtubule Inhibitor Drugs Market Size Forecast by Region
12.1.1 Global Microtubule Inhibitor Drugs Forecast by Region (2023-2028)
12.1.2 Global Microtubule Inhibitor Drugs Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Microtubule Inhibitor Drugs Forecast by Type
12.7 Global Microtubule Inhibitor Drugs Forecast by Application
13 Key Players Analysis
13.1 Eli Lilly and Company
13.1.1 Eli Lilly and Company Company Information
13.1.2 Eli Lilly and Company Microtubule Inhibitor Drugs Product Offered
13.1.3 Eli Lilly and Company Microtubule Inhibitor Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Eli Lilly and Company Main Business Overview
13.1.5 Eli Lilly and Company Latest Developments
13.2 Bristol-Myers Squibb
13.2.1 Bristol-Myers Squibb Company Information
13.2.2 Bristol-Myers Squibb Microtubule Inhibitor Drugs Product Offered
13.2.3 Bristol-Myers Squibb Microtubule Inhibitor Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Bristol-Myers Squibb Main Business Overview
13.2.5 Bristol-Myers Squibb Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Microtubule Inhibitor Drugs Product Offered
13.3.3 Sanofi Microtubule Inhibitor Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Pierre Fabre
13.4.1 Pierre Fabre Company Information
13.4.2 Pierre Fabre Microtubule Inhibitor Drugs Product Offered
13.4.3 Pierre Fabre Microtubule Inhibitor Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Pierre Fabre Main Business Overview
13.4.5 Pierre Fabre Latest Developments
13.5 Eisai
13.5.1 Eisai Company Information
13.5.2 Eisai Microtubule Inhibitor Drugs Product Offered
13.5.3 Eisai Microtubule Inhibitor Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Eisai Main Business Overview
13.5.5 Eisai Latest Developments
13.6 Celgene
13.6.1 Celgene Company Information
13.6.2 Celgene Microtubule Inhibitor Drugs Product Offered
13.6.3 Celgene Microtubule Inhibitor Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Celgene Main Business Overview
13.6.5 Celgene Latest Developments
13.7 Merck
13.7.1 Merck Company Information
13.7.2 Merck Microtubule Inhibitor Drugs Product Offered
13.7.3 Merck Microtubule Inhibitor Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Merck Main Business Overview
13.7.5 Merck Latest Developments
13.8 Roche Holding AG
13.8.1 Roche Holding AG Company Information
13.8.2 Roche Holding AG Microtubule Inhibitor Drugs Product Offered
13.8.3 Roche Holding AG Microtubule Inhibitor Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Roche Holding AG Main Business Overview
13.8.5 Roche Holding AG Latest Developments
13.9 Seagen
13.9.1 Seagen Company Information
13.9.2 Seagen Microtubule Inhibitor Drugs Product Offered
13.9.3 Seagen Microtubule Inhibitor Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Seagen Main Business Overview
13.9.5 Seagen Latest Developments
13.10 Luye Pharma
13.10.1 Luye Pharma Company Information
13.10.2 Luye Pharma Microtubule Inhibitor Drugs Product Offered
13.10.3 Luye Pharma Microtubule Inhibitor Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Luye Pharma Main Business Overview
13.10.5 Luye Pharma Latest Developments
13.11 Shanghai Yizhong
13.11.1 Shanghai Yizhong Company Information
13.11.2 Shanghai Yizhong Microtubule Inhibitor Drugs Product Offered
13.11.3 Shanghai Yizhong Microtubule Inhibitor Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Shanghai Yizhong Main Business Overview
13.11.5 Shanghai Yizhong Latest Developments
13.12 Biostar Pharmaceuticals
13.12.1 Biostar Pharmaceuticals Company Information
13.12.2 Biostar Pharmaceuticals Microtubule Inhibitor Drugs Product Offered
13.12.3 Biostar Pharmaceuticals Microtubule Inhibitor Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Biostar Pharmaceuticals Main Business Overview
13.12.5 Biostar Pharmaceuticals Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Microtubule Inhibitor Drugs Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Microtubule Inhibitor Drugs Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Polymerization Inhibitor
Table 4. Major Players of Depolymerization Inhibitor
Table 5. Major Players of Microtubule Dynamics Inhibitor
Table 6. Major Players of Antibody Drug Conjugates(ADC)
Table 7. Global Microtubule Inhibitor Drugs Sales by Type (2017-2022) & (K Units)
Table 8. Global Microtubule Inhibitor Drugs Sales Market Share by Type (2017-2022)
Table 9. Global Microtubule Inhibitor Drugs Revenue by Type (2017-2022) & ($ million)
Table 10. Global Microtubule Inhibitor Drugs Revenue Market Share by Type (2017-2022)
Table 11. Global Microtubule Inhibitor Drugs Sale Price by Type (2017-2022) & (US$/Unit)
Table 12. Global Microtubule Inhibitor Drugs Sales by Application (2017-2022) & (K Units)
Table 13. Global Microtubule Inhibitor Drugs Sales Market Share by Application (2017-2022)
Table 14. Global Microtubule Inhibitor Drugs Revenue by Application (2017-2022)
Table 15. Global Microtubule Inhibitor Drugs Revenue Market Share by Application (2017-2022)
Table 16. Global Microtubule Inhibitor Drugs Sale Price by Application (2017-2022) & (US$/Unit)
Table 17. Global Microtubule Inhibitor Drugs Sales by Company (2020-2022) & (K Units)
Table 18. Global Microtubule Inhibitor Drugs Sales Market Share by Company (2020-2022)
Table 19. Global Microtubule Inhibitor Drugs Revenue by Company (2020-2022) ($ Millions)
Table 20. Global Microtubule Inhibitor Drugs Revenue Market Share by Company (2020-2022)
Table 21. Global Microtubule Inhibitor Drugs Sale Price by Company (2020-2022) & (US$/Unit)
Table 22. Key Manufacturers Microtubule Inhibitor Drugs Producing Area Distribution and Sales Area
Table 23. Players Microtubule Inhibitor Drugs Products Offered
Table 24. Microtubule Inhibitor Drugs Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Microtubule Inhibitor Drugs Sales by Geographic Region (2017-2022) & (K Units)
Table 28. Global Microtubule Inhibitor Drugs Sales Market Share Geographic Region (2017-2022)
Table 29. Global Microtubule Inhibitor Drugs Revenue by Geographic Region (2017-2022) & ($ millions)
Table 30. Global Microtubule Inhibitor Drugs Revenue Market Share by Geographic Region (2017-2022)
Table 31. Global Microtubule Inhibitor Drugs Sales by Country/Region (2017-2022) & (K Units)
Table 32. Global Microtubule Inhibitor Drugs Sales Market Share by Country/Region (2017-2022)
Table 33. Global Microtubule Inhibitor Drugs Revenue by Country/Region (2017-2022) & ($ millions)
Table 34. Global Microtubule Inhibitor Drugs Revenue Market Share by Country/Region (2017-2022)
Table 35. Americas Microtubule Inhibitor Drugs Sales by Country (2017-2022) & (K Units)
Table 36. Americas Microtubule Inhibitor Drugs Sales Market Share by Country (2017-2022)
Table 37. Americas Microtubule Inhibitor Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 38. Americas Microtubule Inhibitor Drugs Revenue Market Share by Country (2017-2022)
Table 39. Americas Microtubule Inhibitor Drugs Sales by Type (2017-2022) & (K Units)
Table 40. Americas Microtubule Inhibitor Drugs Sales Market Share by Type (2017-2022)
Table 41. Americas Microtubule Inhibitor Drugs Sales by Application (2017-2022) & (K Units)
Table 42. Americas Microtubule Inhibitor Drugs Sales Market Share by Application (2017-2022)
Table 43. APAC Microtubule Inhibitor Drugs Sales by Region (2017-2022) & (K Units)
Table 44. APAC Microtubule Inhibitor Drugs Sales Market Share by Region (2017-2022)
Table 45. APAC Microtubule Inhibitor Drugs Revenue by Region (2017-2022) & ($ Millions)
Table 46. APAC Microtubule Inhibitor Drugs Revenue Market Share by Region (2017-2022)
Table 47. APAC Microtubule Inhibitor Drugs Sales by Type (2017-2022) & (K Units)
Table 48. APAC Microtubule Inhibitor Drugs Sales Market Share by Type (2017-2022)
Table 49. APAC Microtubule Inhibitor Drugs Sales by Application (2017-2022) & (K Units)
Table 50. APAC Microtubule Inhibitor Drugs Sales Market Share by Application (2017-2022)
Table 51. Europe Microtubule Inhibitor Drugs Sales by Country (2017-2022) & (K Units)
Table 52. Europe Microtubule Inhibitor Drugs Sales Market Share by Country (2017-2022)
Table 53. Europe Microtubule Inhibitor Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 54. Europe Microtubule Inhibitor Drugs Revenue Market Share by Country (2017-2022)
Table 55. Europe Microtubule Inhibitor Drugs Sales by Type (2017-2022) & (K Units)
Table 56. Europe Microtubule Inhibitor Drugs Sales Market Share by Type (2017-2022)
Table 57. Europe Microtubule Inhibitor Drugs Sales by Application (2017-2022) & (K Units)
Table 58. Europe Microtubule Inhibitor Drugs Sales Market Share by Application (2017-2022)
Table 59. Middle East & Africa Microtubule Inhibitor Drugs Sales by Country (2017-2022) & (K Units)
Table 60. Middle East & Africa Microtubule Inhibitor Drugs Sales Market Share by Country (2017-2022)
Table 61. Middle East & Africa Microtubule Inhibitor Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 62. Middle East & Africa Microtubule Inhibitor Drugs Revenue Market Share by Country (2017-2022)
Table 63. Middle East & Africa Microtubule Inhibitor Drugs Sales by Type (2017-2022) & (K Units)
Table 64. Middle East & Africa Microtubule Inhibitor Drugs Sales Market Share by Type (2017-2022)
Table 65. Middle East & Africa Microtubule Inhibitor Drugs Sales by Application (2017-2022) & (K Units)
Table 66. Middle East & Africa Microtubule Inhibitor Drugs Sales Market Share by Application (2017-2022)
Table 67. Key Market Drivers & Growth Opportunities of Microtubule Inhibitor Drugs
Table 68. Key Market Challenges & Risks of Microtubule Inhibitor Drugs
Table 69. Key Industry Trends of Microtubule Inhibitor Drugs
Table 70. Microtubule Inhibitor Drugs Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. Microtubule Inhibitor Drugs Distributors List
Table 73. Microtubule Inhibitor Drugs Customer List
Table 74. Global Microtubule Inhibitor Drugs Sales Forecast by Region (2023-2028) & (K Units)
Table 75. Global Microtubule Inhibitor Drugs Sales Market Forecast by Region
Table 76. Global Microtubule Inhibitor Drugs Revenue Forecast by Region (2023-2028) & ($ millions)
Table 77. Global Microtubule Inhibitor Drugs Revenue Market Share Forecast by Region (2023-2028)
Table 78. Americas Microtubule Inhibitor Drugs Sales Forecast by Country (2023-2028) & (K Units)
Table 79. Americas Microtubule Inhibitor Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 80. APAC Microtubule Inhibitor Drugs Sales Forecast by Region (2023-2028) & (K Units)
Table 81. APAC Microtubule Inhibitor Drugs Revenue Forecast by Region (2023-2028) & ($ millions)
Table 82. Europe Microtubule Inhibitor Drugs Sales Forecast by Country (2023-2028) & (K Units)
Table 83. Europe Microtubule Inhibitor Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Middle East & Africa Microtubule Inhibitor Drugs Sales Forecast by Country (2023-2028) & (K Units)
Table 85. Middle East & Africa Microtubule Inhibitor Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 86. Global Microtubule Inhibitor Drugs Sales Forecast by Type (2023-2028) & (K Units)
Table 87. Global Microtubule Inhibitor Drugs Sales Market Share Forecast by Type (2023-2028)
Table 88. Global Microtubule Inhibitor Drugs Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 89. Global Microtubule Inhibitor Drugs Revenue Market Share Forecast by Type (2023-2028)
Table 90. Global Microtubule Inhibitor Drugs Sales Forecast by Application (2023-2028) & (K Units)
Table 91. Global Microtubule Inhibitor Drugs Sales Market Share Forecast by Application (2023-2028)
Table 92. Global Microtubule Inhibitor Drugs Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 93. Global Microtubule Inhibitor Drugs Revenue Market Share Forecast by Application (2023-2028)
Table 94. Eli Lilly and Company Basic Information, Microtubule Inhibitor Drugs Manufacturing Base, Sales Area and Its Competitors
Table 95. Eli Lilly and Company Microtubule Inhibitor Drugs Product Offered
Table 96. Eli Lilly and Company Microtubule Inhibitor Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 97. Eli Lilly and Company Main Business
Table 98. Eli Lilly and Company Latest Developments
Table 99. Bristol-Myers Squibb Basic Information, Microtubule Inhibitor Drugs Manufacturing Base, Sales Area and Its Competitors
Table 100. Bristol-Myers Squibb Microtubule Inhibitor Drugs Product Offered
Table 101. Bristol-Myers Squibb Microtubule Inhibitor Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 102. Bristol-Myers Squibb Main Business
Table 103. Bristol-Myers Squibb Latest Developments
Table 104. Sanofi Basic Information, Microtubule Inhibitor Drugs Manufacturing Base, Sales Area and Its Competitors
Table 105. Sanofi Microtubule Inhibitor Drugs Product Offered
Table 106. Sanofi Microtubule Inhibitor Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 107. Sanofi Main Business
Table 108. Sanofi Latest Developments
Table 109. Pierre Fabre Basic Information, Microtubule Inhibitor Drugs Manufacturing Base, Sales Area and Its Competitors
Table 110. Pierre Fabre Microtubule Inhibitor Drugs Product Offered
Table 111. Pierre Fabre Microtubule Inhibitor Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 112. Pierre Fabre Main Business
Table 113. Pierre Fabre Latest Developments
Table 114. Eisai Basic Information, Microtubule Inhibitor Drugs Manufacturing Base, Sales Area and Its Competitors
Table 115. Eisai Microtubule Inhibitor Drugs Product Offered
Table 116. Eisai Microtubule Inhibitor Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 117. Eisai Main Business
Table 118. Eisai Latest Developments
Table 119. Celgene Basic Information, Microtubule Inhibitor Drugs Manufacturing Base, Sales Area and Its Competitors
Table 120. Celgene Microtubule Inhibitor Drugs Product Offered
Table 121. Celgene Microtubule Inhibitor Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 122. Celgene Main Business
Table 123. Celgene Latest Developments
Table 124. Merck Basic Information, Microtubule Inhibitor Drugs Manufacturing Base, Sales Area and Its Competitors
Table 125. Merck Microtubule Inhibitor Drugs Product Offered
Table 126. Merck Microtubule Inhibitor Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 127. Merck Main Business
Table 128. Merck Latest Developments
Table 129. Roche Holding AG Basic Information, Microtubule Inhibitor Drugs Manufacturing Base, Sales Area and Its Competitors
Table 130. Roche Holding AG Microtubule Inhibitor Drugs Product Offered
Table 131. Roche Holding AG Microtubule Inhibitor Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 132. Roche Holding AG Main Business
Table 133. Roche Holding AG Latest Developments
Table 134. Seagen Basic Information, Microtubule Inhibitor Drugs Manufacturing Base, Sales Area and Its Competitors
Table 135. Seagen Microtubule Inhibitor Drugs Product Offered
Table 136. Seagen Microtubule Inhibitor Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 137. Seagen Main Business
Table 138. Seagen Latest Developments
Table 139. Luye Pharma Basic Information, Microtubule Inhibitor Drugs Manufacturing Base, Sales Area and Its Competitors
Table 140. Luye Pharma Microtubule Inhibitor Drugs Product Offered
Table 141. Luye Pharma Microtubule Inhibitor Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 142. Luye Pharma Main Business
Table 143. Luye Pharma Latest Developments
Table 144. Shanghai Yizhong Basic Information, Microtubule Inhibitor Drugs Manufacturing Base, Sales Area and Its Competitors
Table 145. Shanghai Yizhong Microtubule Inhibitor Drugs Product Offered
Table 146. Shanghai Yizhong Microtubule Inhibitor Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 147. Shanghai Yizhong Main Business
Table 148. Shanghai Yizhong Latest Developments
Table 149. Biostar Pharmaceuticals Basic Information, Microtubule Inhibitor Drugs Manufacturing Base, Sales Area and Its Competitors
Table 150. Biostar Pharmaceuticals Microtubule Inhibitor Drugs Product Offered
Table 151. Biostar Pharmaceuticals Microtubule Inhibitor Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 152. Biostar Pharmaceuticals Main Business
Table 153. Biostar Pharmaceuticals Latest Developments
List of Figures
Figure 1. Picture of Microtubule Inhibitor Drugs
Figure 2. Microtubule Inhibitor Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Microtubule Inhibitor Drugs Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Microtubule Inhibitor Drugs Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Microtubule Inhibitor Drugs Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Polymerization Inhibitor
Figure 10. Product Picture of Depolymerization Inhibitor
Figure 11. Product Picture of Microtubule Dynamics Inhibitor
Figure 12. Product Picture of Antibody Drug Conjugates(ADC)
Figure 13. Global Microtubule Inhibitor Drugs Sales Market Share by Type in 2021
Figure 14. Global Microtubule Inhibitor Drugs Revenue Market Share by Type (2017-2022)
Figure 15. Microtubule Inhibitor Drugs Consumed in Breast Cancer
Figure 16. Global Microtubule Inhibitor Drugs Market: Breast Cancer (2017-2022) & (K Units)
Figure 17. Microtubule Inhibitor Drugs Consumed in Stomach Cancer
Figure 18. Global Microtubule Inhibitor Drugs Market: Stomach Cancer (2017-2022) & (K Units)
Figure 19. Microtubule Inhibitor Drugs Consumed in Lung Cancer
Figure 20. Global Microtubule Inhibitor Drugs Market: Lung Cancer (2017-2022) & (K Units)
Figure 21. Microtubule Inhibitor Drugs Consumed in Esophageal Cancer
Figure 22. Global Microtubule Inhibitor Drugs Market: Esophageal Cancer (2017-2022) & (K Units)
Figure 23. Microtubule Inhibitor Drugs Consumed in Others
Figure 24. Global Microtubule Inhibitor Drugs Market: Others (2017-2022) & (K Units)
Figure 25. Global Microtubule Inhibitor Drugs Sales Market Share by Application (2017-2022)
Figure 26. Global Microtubule Inhibitor Drugs Revenue Market Share by Application in 2021
Figure 27. Microtubule Inhibitor Drugs Revenue Market by Company in 2021 ($ Million)
Figure 28. Global Microtubule Inhibitor Drugs Revenue Market Share by Company in 2021
Figure 29. Global Microtubule Inhibitor Drugs Sales Market Share by Geographic Region (2017-2022)
Figure 30. Global Microtubule Inhibitor Drugs Revenue Market Share by Geographic Region in 2021
Figure 31. Global Microtubule Inhibitor Drugs Sales Market Share by Region (2017-2022)
Figure 32. Global Microtubule Inhibitor Drugs Revenue Market Share by Country/Region in 2021
Figure 33. Americas Microtubule Inhibitor Drugs Sales 2017-2022 (K Units)
Figure 34. Americas Microtubule Inhibitor Drugs Revenue 2017-2022 ($ Millions)
Figure 35. APAC Microtubule Inhibitor Drugs Sales 2017-2022 (K Units)
Figure 36. APAC Microtubule Inhibitor Drugs Revenue 2017-2022 ($ Millions)
Figure 37. Europe Microtubule Inhibitor Drugs Sales 2017-2022 (K Units)
Figure 38. Europe Microtubule Inhibitor Drugs Revenue 2017-2022 ($ Millions)
Figure 39. Middle East & Africa Microtubule Inhibitor Drugs Sales 2017-2022 (K Units)
Figure 40. Middle East & Africa Microtubule Inhibitor Drugs Revenue 2017-2022 ($ Millions)
Figure 41. Americas Microtubule Inhibitor Drugs Sales Market Share by Country in 2021
Figure 42. Americas Microtubule Inhibitor Drugs Revenue Market Share by Country in 2021
Figure 43. United States Microtubule Inhibitor Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 44. Canada Microtubule Inhibitor Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 45. Mexico Microtubule Inhibitor Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 46. Brazil Microtubule Inhibitor Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 47. APAC Microtubule Inhibitor Drugs Sales Market Share by Region in 2021
Figure 48. APAC Microtubule Inhibitor Drugs Revenue Market Share by Regions in 2021
Figure 49. China Microtubule Inhibitor Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 50. Japan Microtubule Inhibitor Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 51. South Korea Microtubule Inhibitor Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 52. Southeast Asia Microtubule Inhibitor Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 53. India Microtubule Inhibitor Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 54. Australia Microtubule Inhibitor Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 55. Europe Microtubule Inhibitor Drugs Sales Market Share by Country in 2021
Figure 56. Europe Microtubule Inhibitor Drugs Revenue Market Share by Country in 2021
Figure 57. Germany Microtubule Inhibitor Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 58. France Microtubule Inhibitor Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 59. UK Microtubule Inhibitor Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 60. Italy Microtubule Inhibitor Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 61. Russia Microtubule Inhibitor Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 62. Middle East & Africa Microtubule Inhibitor Drugs Sales Market Share by Country in 2021
Figure 63. Middle East & Africa Microtubule Inhibitor Drugs Revenue Market Share by Country in 2021
Figure 64. Egypt Microtubule Inhibitor Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 65. South Africa Microtubule Inhibitor Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 66. Israel Microtubule Inhibitor Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 67. Turkey Microtubule Inhibitor Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 68. GCC Country Microtubule Inhibitor Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 69. Manufacturing Cost Structure Analysis of Microtubule Inhibitor Drugs in 2021
Figure 70. Manufacturing Process Analysis of Microtubule Inhibitor Drugs
Figure 71. Industry Chain Structure of Microtubule Inhibitor Drugs
Figure 72. Channels of Distribution
Figure 73. Distributors Profiles

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/

H&I Global Research

微小管阻害薬の世界市場2022-2028：重合阻害剤、解重合阻害剤、微小管ダイナミクス阻害剤、抗体薬物複合体（ADC）

グローバル市場調査会社